Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Pentostatin (Nipent) in T-cell lymphomas.

¹Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Seminars in Oncology

|July 6, 2000

Summary

Pentostatin shows activity in T-cell lymphomas, with 17 of 24 patients responding. Further research is warranted for this lymphocytotoxic agent in treating these challenging hematologic malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.

ESMO open·2026

Same author

Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.

ESMO open·2026

Same author

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP).

ESMO open·2025

Same author

The best management for most patients with incurable cancer is on a clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Area of Science:

Oncology
Hematology
Pharmacology

Background:

Pentostatin is known for its efficacy in hairy cell leukemia due to its high lymphocytotoxicity.
T-cell lymphomas represent a group of hematologic malignancies with limited treatment options, especially in heavily pretreated patients.

Observation:

A clinical trial evaluated pentostatin in patients with heavily pretreated cutaneous and peripheral T-cell lymphomas.
The drug was administered intravenously at doses of 3.75 or 5.0 mg/m2/d for 3 days every 3 weeks.

Findings:

Pentostatin demonstrated significant activity, with 17 out of 24 evaluable patients achieving a response (complete or partial remission).
Common toxicities observed included granulocytopenia, nausea, renal insufficiency, CD4 suppression, and delayed herpes zoster.

Implications:

Pentostatin is an active therapeutic agent for T-cell lymphomas, suggesting its potential role in managing these diseases.
Further clinical investigation of pentostatin in T-cell lymphomas is justified based on these promising preliminary results.

Related Experiment Videos